Overview

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

Status:
Completed
Trial end date:
2018-11-28
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine: - The safety of tirzepatide and any side effects that might be associated with it. - How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. - How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide